{"id":"https://openalex.org/W2515211445","doi":"https://doi.org/10.1016/j.imbio.2016.06.078","title":"Design and preclinical characterization of ALXN1210: A next generation anti-C5 monoclonal antibody with improved pharmacokinetics and duration of action","display_name":"Design and preclinical characterization of ALXN1210: A next generation anti-C5 monoclonal antibody with improved pharmacokinetics and duration of action","alternate_titles":[],"publication_year":2016,"publication_date":"2016-08-11","ids":{"openalex":"https://openalex.org/W2515211445","doi":"https://doi.org/10.1016/j.imbio.2016.06.078","mag":"2515211445"},"language":"en","primary_location":{"id":"doi:10.1016/j.imbio.2016.06.078","doi":"https://doi.org/10.1016/j.imbio.2016.06.078","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.imbio.2016.06.078","pdf_url":null,"source":{"id":"https://openalex.org/S164377831","display_name":"Immunobiology","issn_l":"0171-2985","issn":["0171-2985","1878-3279"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunobiology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2515211445"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048121286","display_name":"Douglas L. Sheridan","orcid":"https://orcid.org/0000-0001-9505-1668","observed_orcids":["https://orcid.org/0000-0001-9505-1668"]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Douglas Sheridan","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., New Haven, CT, USA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114046309","display_name":"Zhao-Xue Yu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Zhao-Xue Yu","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., New Haven, CT, USA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010328748","display_name":"Yuchun Zhang","orcid":"https://orcid.org/0000-0002-9825-6500","observed_orcids":["https://orcid.org/0000-0002-9825-6500"]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yuchun Zhang","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., New Haven, CT, USA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Rekha Patel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rekha Patel","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., New Haven, CT, USA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113529043","display_name":"Melissa A. Lasaro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Melissa Lasaro","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., New Haven, CT, USA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005023102","display_name":"Keith R. Bouchard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Keith Bouchard","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., New Haven, CT, USA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047778095","display_name":"Bruce A. Andrien","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bruce Andrien","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., New Haven, CT, USA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112467653","display_name":"Andre J. Marozsan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andre Marozsan","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., New Haven, CT, USA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100364922","display_name":"Yi Wang","orcid":"https://orcid.org/0000-0002-2031-087X","observed_orcids":["https://orcid.org/0000-0002-2031-087X","https://orcid.org/0000-0002-5765-4983"]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yi Wang","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., New Haven, CT, USA","institution_ids":["https://openalex.org/I4210125492"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066510235","display_name":"Paul P. Tamburini","orcid":"https://orcid.org/0000-0003-3187-2314","observed_orcids":["https://orcid.org/0000-0003-3187-2314"]},"institutions":[{"id":"https://openalex.org/I4210125492","display_name":"Alexion Pharmaceuticals (United States)","ror":"https://ror.org/031ywxc85","country_code":"US","type":"company","lineage":["https://openalex.org/I4210125492"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Paul Tamburini","raw_affiliation_strings":["Alexion Pharmaceuticals, Inc., New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alexion Pharmaceuticals, Inc., New Haven, CT, USA","institution_ids":["https://openalex.org/I4210125492"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5048121286"],"corresponding_institution_ids":["https://openalex.org/I4210125492"],"apc_list":{"value":2840,"currency":"USD","value_usd":2840},"apc_paid":null,"fwci":0.6457,"has_fulltext":false,"cited_by_count":6,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.62872282,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":95},"biblio":{"volume":"221","issue":"10","first_page":"1158","last_page":"1158"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.00559999980032444,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14245","display_name":"Biomarkers in Disease Mechanisms","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-c5-monoclonal-antibody","display_name":"anti-C5 monoclonal antibody","score":0.8960000276565552},{"id":"https://openalex.org/keywords/complement-c5","display_name":"complement C5","score":0.7400000095367432},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8539999723434448},{"id":"https://openalex.org/keywords/duration-of-action","display_name":"duration of action","score":0.9800000190734863},{"id":"https://openalex.org/keywords/antibody-design","display_name":"antibody design","score":0.6269999742507935},{"id":"https://openalex.org/keywords/preclinical-characterization","display_name":"preclinical characterization","score":0.7390000224113464},{"id":"https://openalex.org/keywords/complement-inhibition","display_name":"complement inhibition","score":0.621999979019165}],"concepts":[{"id":"https://openalex.org/C2777346216","wikidata":"https://www.wikidata.org/wiki/Q1479494","display_name":"Paroxysmal nocturnal hemoglobinuria","level":2,"score":0.7115091681480408},{"id":"https://openalex.org/C111684460","wikidata":"https://www.wikidata.org/wiki/Q334848","display_name":"Complement system","level":3,"score":0.7045235633850098},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6631787419319153},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.6135196685791016},{"id":"https://openalex.org/C2777991916","wikidata":"https://www.wikidata.org/wiki/Q421617","display_name":"Eculizumab","level":4,"score":0.486073762178421},{"id":"https://openalex.org/C2777637130","wikidata":"https://www.wikidata.org/wiki/Q17165460","display_name":"Atypical hemolytic uremic syndrome","level":4,"score":0.4376063942909241},{"id":"https://openalex.org/C189446657","wikidata":"https://www.wikidata.org/wiki/Q4736500","display_name":"Alternative complement pathway","level":4,"score":0.43113717436790466},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.3803003430366516},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.36929354071617126},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3679453730583191},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3285275399684906},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.32202398777008057}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.imbio.2016.06.078","doi":"https://doi.org/10.1016/j.imbio.2016.06.078","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.imbio.2016.06.078","pdf_url":null,"source":{"id":"https://openalex.org/S164377831","display_name":"Immunobiology","issn_l":"0171-2985","issn":["0171-2985","1878-3279"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunobiology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8371999859809875,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2439522486","https://openalex.org/W2513752273","https://openalex.org/W2510115740","https://openalex.org/W6946230414","https://openalex.org/W2980798189","https://openalex.org/W2163295341","https://openalex.org/W2079452250","https://openalex.org/W3112630471","https://openalex.org/W258721760","https://openalex.org/W2981492072"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2515211445","counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-09-16T00:00:00"}
